Walter Kinney

Walter Kinney

Auto-generated profile, based on publicly available information

Walter Kinney

Kaiser Permanente Northern California, Oakland, CA, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
NWNicolas Wentzensen
Nicolas Wentzensen
BLBernd Lahrmann
Bernd Lahrmann
MCMegan A Clarke
Megan A Clarke
WKWalter Kinney
Walter Kinney
DTDiane Tokugawa
Diane Tokugawa
NGNiels Grabe
Niels Grabe
With the advent of primary human papillomavirus testing followed by cytology for cervical cancer screening, visual interpretation of cytology slides remains the last subjective analysis step and suffers from low sensitivity and reproducibility. We developed a cloud-based whole-slide imaging platform with a deep-learning classifier for p16/Ki-67 dual-stained (DS) slides trained on biopsy-based gold standards. We compared it with conventional Pap and manual DS in 3 epidemiological studies of cervical and anal precancers from Kaiser Permanente Northern California and the University of Oklahoma comprising 4253 patients. All statistical tests were 2-sided. In independent validation at Kaiser Permanente Northern California, artificial intelligence (AI)-based DS had lower positivity than cytology (P < .001) and manual DS (P < .001) with equal sensitivity and substantially higher specificity compared with both Pap (P < .001) and manual DS (P < .001), respectively. Compared with Pap, AI-based DS reduced referral to colposcopy by one-third (41.9% vs 60.1%, P < .001). At a higher cutoff, AI-based DS had similar performance to high-grade squamous intraepithelial lesions cytology, indicating a risk high enough to allow for immediate treatment. The classifier was robust, showing comparable performance in 2 cytology systems and in anal cytology. Automated DS evaluation removes the remaining subjective component from cervical cancer screening and delivers consistent quality for providers and patients. Moving from Pap to automated DS substantially reduces the number of colposcopies and also achieves excellent performance in a simulated fully vaccinated population. Through cloud-based implementation, this approach is globally accessible. Our results demonstrate that AI not only provides automation and objectivity but also delivers a substantial benefit for women by reduction of unnecessary colposcopies.

1 January 2003 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
MMMarie Grisham Miller
Marie Grisham Miller
HSHai-Yen Sung
Hai-Yen Sung
GSGeorge F. Sawaya
George F. Sawaya
KKKathleen A. Kearney
Kathleen A. Kearney
WKWalter Kinney
Walter Kinney
RHRobert A. Hiatt
Robert A. Hiatt

22 September 2016 in Cancer
Verified
Journal Article
Open access
PDF file
MSMichelle I. Silver
Michelle I. Silver
MSMark Schiffman
Mark Schiffman
BFBarbara Fetterman
Barbara Fetterman
NPNancy E. Poitras
Nancy E. Poitras
JGJulia C. Gage
Julia C. Gage
PCPhilip E Castle
Philip E Castle
BACKGROUND: The objective of cervical screening is to detect and treat precancer to prevent cervical cancer mortality and morbidity while minimizing overtreatment of benign human papillomavirus (HPV) infections and related minor abnormalities. HPV/cytology cotesting at extended 5‐year intervals currently is a recommended screening strategy in the United States, but the interval extension is controversial. In the current study, the authors examined the impact of a decade of an alternative, 3‐year cotesting, on rates of precancer and cancer at Kaiser Permanente Northern California. The effect on screening efficiency, defined as numbers of cotests/colposcopy visits needed to detect a precancer, also was considered.METHODS: Two cohorts were defined. The “open cohort” included all women screened at least once during the study period; > 1 million cotests were performed. In a fixed “long‐term screening cohort,” the authors considered the cumulative impact of repeated screening at 3‐year intervals by restricting the cohort to women first cotested in 2003 through 2004 (ie, no women entering screening later were added to this group).RESULTS: Detection of cervical intraepithelial neoplasia 3/adenocarcinoma in situ (CIN3/AIS) increased in the open cohort (2004‐2006: 82.0/100,000 women screened; 2007‐2009: 140.6/100,000 women screened; and 2010‐2012: 126.0/100,000 women screened); cancer diagnoses were unchanged. In the long‐term screening cohort, the detection of CIN3/AIS increased and then decreased to the original level (2004‐2006: 80.5/100,000 women screened; 2007‐2009: 118.6/100,000 women screened; and 2010‐2012: 84.9./100,000 women screened). The number of cancer diagnoses was found to decrease. When viewed in terms of screening efficiency, the number of colposcopies performed to detect a single case of CIN3/AIS increased in the cohort with repeat screening.CONCLUSIONS: Repeated cotesting at a 3‐year interval eventually lowers population rates of precancer and cancer. However, a greater number of colposcopies are required to detect a single precancer. Cancer 2016;122:3682‐6. © 2016 American Cancer Society.

3 June 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
SDShrutikona Das
Shrutikona Das
NWNicolas Wentzensen
Nicolas Wentzensen
GSGeorge F Sawaya
George F Sawaya
DEDidem Egemen
Didem Egemen
ALAlexander Locke
Alexander Locke
LCLi Cheung
Li Cheung
Implementation of primary human papillomavirus (HPV) testing has been slow in the United States perhaps because of concerns of decreased sensitivity compared with concurrent HPV and cytology testing (“cotesting”). We used the National Breast and Cervical Cancer Early Detection Program and the Kaiser Permanente of Northern California cohort to quantify potential trade-offs with primary HPV compared with cotesting in 4 US populations with differing precancer or cancer prevalence. In all settings, cotesting required more lab tests and more colposcopies compared with primary HPV testing. Additional cervical intraepithelial neoplasia grade 3 or cancer immediately detected from cotesting vs primary HPV decreased with decreasing population-average cervical intraepithelial neoplasia grade 3 or cancer prevalence from 71 per 100 000 screened among never or rarely screened individuals in the National Breast and Cervical Cancer Early Detection Program (prevalence = 1212 per 100 000) to 4 per 100 000 screened among individuals with prior HPV-negative results in Kaiser Permanente of Northern California (prevalence = 86 per 100 000). These data suggest that cotesting confer an unfavorable benefit-to-harm ratio over primary HPV testing.

8 September 2021 in Obstetrics & Gynecology
Verified
Journal Article
Open access
ALAlexander Locke
Alexander Locke
NSNina R. Shah
Nina R. Shah
BFBarbara Sct (Asccp) Fetterman
Barbara Sct (Asccp) Fetterman
NPNancy Bs Poitras
Nancy Bs Poitras
SWSoora Wi
Soora Wi
TLThomas Lorey
Thomas Lorey
The majority of cervical cancers after Pap-test–positive, human papillomavirus test–negative co-tests are symptomatic or clinically apparent.

1 March 2013 in Obstetrical & Gynecological Survey
Verified
Journal Article
Closed access
HDHelen Dinkelspiel
Helen Dinkelspiel
BFBarbara Fetterman
Barbara Fetterman
NPNancy Poitras
Nancy Poitras
WKWalter Kinney
Walter Kinney
JCJ. Thomas Cox
J. Thomas Cox
PCPhilip E Castle
Philip E Castle
Several national organizations have recommended stopping cervical cancer screening or no longer screening low-risk women at the age of 65 or 70 years following a history of normal screens. In 1996, Kaiser Permanente Northern California (KPNC) stopped screening women at age 65 years who had 3 consecutive negative Papanicolaou (Pap) smears. The decision of KPNC to stop screening in this population was based on observational data for about 1.4 million female members for the years 1988 to 1994. One long-term prospective study showed that a single human papillomavirus (HPV) test forecasts CIN2+ and the subsequent diagnosis of cancer for 18 years of follow-up. This and other observations suggested that HPV testing was useful for determining which women could safely exit screening. In 2003, a single negative HPV cotest was added as an alternative criterion for exiting screening in women 65 years or older. A number of studies have suggested the risk of cancer after 3 consecutive negative Pap tests is higher than the risk of cancer after a negative cotest. There is little direct evidence for or against the safety of exiting screening in this population. This observational study investigated the safety of stopping antecedent screening of women 65 years or older diagnosed with cervical cancer. Databases at KPNC and the regional Cancer Registry were used to examine screening histories of women 65 years or older who were diagnosed with cervical cancer between 2003 and 2008. During the 6-year study period, 56 KPNC members 65 years or older were diagnosed with invasive cervical cancer. Over this same period, there were 1,323,100 member-years of women 65 years or older. The annual risk of invasive cervical cancer in women 65 years or older in this population was 4.2/100,000 per year; 59% (33/56) of the cancers were diagnosed in women who had 1 or more prior negative PAP smears. Fourteen (25%) of the 33 women with invasive cervical cancer had 3 consecutive negative Pap smears before diagnosis. Among the 46,401 women with 1 or more negative cotests at 65 years or older, 3 had a subsequent diagnosis of invasive cancer during 132,639 women-years of follow-up (2.3/100,000 per year). These findings show that most women diagnosed with cervical cancer at 65 years or older fail to meet the criteria to stop screening. As with other age groups, a few cervical cancers will occur in women 65 years or older despite multiple negative tests. There is no evidence that continued screening in this older population can prevent these cancers.